There have been a few threads on teens and nighttime checks so I’d thought I’d share a recent experience. A lot of this is known and I may even have one or two things wrong (feel free to correct if you spot an error), but just wanted to share my experience and thoughts. So I recently heard Ed Damiano speak and spent a lot of time chatting with him afterwards. I’ve read about the Bionic Pancreas on line but it was really cool to see and hear in person. My random thoughts in no particular order … - I really liked him. He’s got a lot invested so his outlook may be overly rosy, but he struck me as a smart, high-energy, sincere, caring person. - He discussed two versions of the BP. Dual hormone (insulin and glucagon) and single hormone (insulin only). The dual has been more rigorously trialed but he seems equally excited about the single. - He has a 16 year-old T1D son. He kept referencing his personal deadline of FDA approval in 22 months, which is when his son goes off to college. - When pushed on handicapping the odds of meeting the 22 month deadline (single hormone version), his best guess was he will miss by two semesters. Like most of us, he worries a lot about those two semesters. - When asked about the biggest threat to not having the dual hormone BP out in 2018 or 2019, he said the biggest threat is the single hormone BP. - The single hormone BP works extremely well at reducing BG volatility, achieving an A1C of 7.0 and reducing time in hypo (under 60) to 1% of the time. He questions whether private pay will be willing to step up to reimburse for a dual hormone BP that “only” achieves A1C of 6.5 and reduces time in hypo to 0.5% of the time. - I expressed concern about nighttime BG’s when sending my son off to college with a single hormone BP. His response was “not me”. He went on to describe how this is a completely different animal in so many ways than Medtronic’s cut-the-basal off technology. I would do it a disservice to try to explain, but it had something to do with patented complex algorithms and 288 readings and potential basal/bolus adjustments a day. - I found it interesting that his son has never worn the BP and never participated in any of the trials. He doesn’t want any hint of conflict of interest. - A member of his team with T1D also spoke about his experience with the 5-day trial. It was fascinating. After the trial he turned in his pump and cried on the drive home. - As for stable glucagon, he was very confident that waiting on that would not be an issue. He discussed two biotech firms with glucagon’s deep in development that are more stable than insulin (1 year shelf life with no refrigeration necessary). Again, his confidence gave me confidence. - The dual hormone BP that will eventually make its way to market is about the size of an iphone but a bit wider. There were some very cool features such as the pre-filled insulin vial won’t fit into the slot for pre-filled glucagon viles for obvious safety reasons. - The dual hormone BP will have a single infusion site with two tubes. - He seemed to have a very active dialogue with the FDA which should improve the odds of success down the road. An interesting for instance, is that he originally planned for the BP to be for ages 6 and older. The FDA (maybe comforted by Dexcom’s successes) asked “why? There shouldn’t be a pediatric cut-off”. Anyway, it was an interesting evening to say the least. Maybe the pixie dust will wear off soon but I feel a tad like I did during the 12 months or so post dx … somewhat optimistic about technology. Naive? Maybe. But I'll enjoy while it lasts.